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Abstract
Human interleukin-15 (hIL15) has anti-tumor activities, but it is not convenient for tumor
treatment because of its short half-life. A gene therapy for mouse lung cancer using an adenovirus
vector expressing IL15 has been reported. However, adenovirus vector-mediated gene therapy can
provoke cellular toxicity and inflammatory reactions. The recombinant adenovirus-associated
vector 2 (rAAV2) is safer due to minimal cellular toxicity and immune response. In order to
demonstrate that gene therapy can be used safely and successfully for human cancer treatment, the
rAAV2 expressing hIL15 gene (rAAV2-hIL15) is applied for human cervical cancer, HeLa cell, in this
study. This study successfully demonstrates that rAAV2-hIL15 can express IL15 with bioactivities
in vitro and in vivo. In conclusion, our studies show that human cervical cancers are inhibited on
animal model with rAAV2-hIL15 treatment and provide a safer and important reference for human
cancer gene therapy.
Background
There had been many studies that considered immuno-
therapy as a potent method for the treatment of cancer
and this method inhibits tumor growth [1,2]. Both inter-
leukin-2 (IL2) and interleukin-15 (IL15) have been used
for cancer immunotherapy [3,4]. However, previous stud-
ies indicated that IL2 displayed a significant toxicity in
immunotherapy after systemic administration of high-
dose IL2 [5,6]. IL15 is a 14–15 Kd immunostimulatory
cytokine which belongs to a four α-helix cytokine family
[7,8]. Using IL15 for cancer immunotherapy based on NK
cell activity and immunoglobulin production had been
demonstrated previously [9,10]. Repeated daily injection
is required because of the short biological half-life using
IL15 administration [11-13]. In addition, some studies
showed that tumor cells engineered to secrete IL15 can
inhibit tumor growth on animal models [6,14]. That
would suggest that replacing daily administration using
gene therapy may be useful for cancer immuno-
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rus vector expressing IL15 gene can inhibit lung cancer in
mouse [15]. However, adenovirus vector is not suitable
for human gene therapy due to its cytoxicity and inflam-
matory response [16]. Hence this study used a safer viral
vector (rAAV2) expressing hIL15 for human cervical can-
cer treatment.
Many studies have demonstrated that rAAV2 is a good
choice for gene therapy because of the attractive features
offered by this gene delivery system. The major advan-
tages of rAAV2's are nonpathogenic in human with low
immunogenicity compared with the other viral delivery
systems [17,18]. Moreover, rAAV2s can infect both the
dividing and quiescent cells by inducing a long-term sta-
ble gene expression in a wide variety of tissues [19-21].
Recently, rAAV2 has been demonstrated safe in human
clinical trails [22,23]. Based on these attractive features,
we chose rAAV2 delivery system to express hIL15 for can-
cer immunotherapy.
Previous study has indicated that rAAV2 vector is difficult
to scale up [24]. In this study, we used the helper-free sys-
tem to produce rAAV2 expressing human IL15 gene
(rAAV2-hIL15) [25] and purified the rAAV2-hIL15 with a
single-step gravity-flow column (SSCP method) [26]. The
purified rAAV2-hIL15 could exert bioactivities in vitro and
in vivo. Furthermore, our data demonstrated that single
intramuscular injection of rAAV2-hIL15 can effectively
inhibit HeLa cells growth on nude mouse model. This is
the first research study that used a safe viral vector rAAV2
expressing human IL15 gene for cancer immunotherapy
and successfully inhibited tumor cell growth on an animal
model. This study can provide a safe and effective refer-
ence for cancer gene therapy in the future
Materials and methods
Culture Conditions
HeLa (human cervical cancer), 293 (human embryonic
kidney) and HT1080 (human fibrosarcoma) cells were
purchased from Bioresource Collection and Research
Center (BCRC, Taiwan) and cultured in Dulbecco's mod-
ified Eagle's medium (DMEM) supplemented with 10%
fetal bovine serum, 2 mM L-glutamine, 100 IU/ml penicil-
lin/streptomycin, 1 mM sodium pyruvate, and 0.1 mM
non-essential amino acids. HT2 (murine IL2/IL15
dependent) cells were purchased from BCRC and cultured
in RPMI 1640 medium supplemented with 10% fetal
bovine serum, 2 mM L-glutamine, 100 IU/ml penicillin/
streptomycin, 1 mM sodium pyruvate, and 0.1 mM non-
essential amino acids. In addition, HT2 cells were supple-
mented with 1 μg/ml human recombinant IL15 protein
(Santa Cruz Biotechnology, Santa Cruz, California, USA).
DMEM, RPMI, fetal bovine serum, L-glutamine, penicil-
lin/streptomycin, sodium pyruvate and non-essential
amino acids were bought from Invitrogen (Carlsbad, Cal-
ifornia, USA).
Plasmids and Plasmid Construction
The rAAV2 helper-free system, containing packaging plas-
mid pAAV-MCS plasmid, pAAV-RC plasmid, pHelper,
pAAV-hrGFP plasmid was purchased from Strategene (La
Jolla, California, USA). The plasmid containing human
IL15 gene (hIL15) was provided thru the kindness of Dr L.
KW (National Chiao Tung University, Taiwan). The hIL15
containing EcoR I and BamH I sites was amplified for
cloning using the polymerase chain reaction. Oligonucle-
otide primers containing EcoR I and BamH I sites were
synthesized as follows: sense primer: 5'GAATTC AAA GAA
TTC ATG TAC AGG ATG CAA CTC CT, and anti-sense
primer, 3'GGATCC AAA GGA TCC TTA AGA AGT GTT
GAT GAA CAT TTG G. The PCR conditions used a thermal
profile of denaturing at 95°C for 30 sec, annealing at
95°C for 30 sec, and extending at 72°C for 30 sec for 30
cycles, followed by 72°C for 10 min. The amplified hIL15
cDNA was inserted between the EcoR I and BamH I sites
of pAAV-MCS to yield pAAV-hIL15 plasmid.
Production of rAAV2
Production of rAAV2-hIL15 and rAAV2-hrGFP was done
in the helper-free system as described previously [25]. For
rAAV2-hIL15 production, 293 cells were cultured on fifty
15-cm-dishes and transfected with calcium chloride with
2 mg pAAV-hIL15 plasmid, 2 mg pAAV-RC plasmid and 2
mg pAAV-Helper plasmid. For rAAV2-hrGFP production,
293 cells were cultured on fifty 15-cm-dishes and trans-
fected with calcium chloride with 2 mg pAAV-hrGFP plas-
mid, 2 mg pAAV-RC plasmid and 2 mg pAAV-Helper
plasmid. After 65 hours of transfection, rAAV2-hIL15 and
rAAV2-hrGFP were produced in 293 cells.
Purification of rAAV2
Purification of rAAV2-hIL15 and rAAV2-hrGFP was done
using a single-step column purification (SSCP) method
[26]. The rAAV2 was concentrated to about 1 ml with an
Amicon Ultra-15 centrifugal filter (Millipore, Billerica,
MA) and stored at -80°C. Finally, the viral titers of rAAV2
were determined by Real-time PCR method as described
previously [24]. A total of 2–5 × 1012 genomic particles of
rAAV2 can be obtained from fifty 15-cm-dishes. Purified
rAAV2 (rAAV2-hIL15 and rAAV2-hrGFP) was determined
by loading 1010 viral particles on 10% SDS gel [26] and
viral proteins (VP1, VP2 and VP3) were detected by silver
stain
Quantification of IL15 Expression
HT1080 cells can be infected with AAV2 easily for the pro-
duction of AAV2 expressing genes. In this study, HT1080
(1.5 × 105) cells were divided into three groups and cul-
tured on 6-well-plates, then each group was treated withPage 2 of 8
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hrGFP (1013 viral particles/ml) and PBS, respectively. After
2 days, the media were collected for quantification of
IL15. IL15 titers were determined using an ELISA kit (Bio-
source, Camarillo, California, USA).
In Vitro Bioactivity Assay
HT2 cells are IL2/IL15 dependent cells and can not survive
without IL2 or IL15 supply. Therefore growth of HT2 cells
is determined by the IL15 bioactivity. HT2 cells were
divided into three groups and their survival rates were
determined by using MTS assay (Promega, Madison, Wis-
consin, USA) under an optical density 490 nm. The first
group of HT2 cells was cultured with the media obtained
from 100 μl of rAAV2-hIL15 (1013 viral particles/ml)-
infected HT1080 cells. The second group was cultured
with the media obtained from 100 μl of rAAV2-hrGFP
(1013 viral particles/ml)-infected HT1080 cells. The third
group of HT2 cells was cultured with the media obtained
from purified 1 μg/ml human recombinant IL15-incu-
bated HT1080 cells (This group was used as the positive
control). These were then observed under the microscope.
In Vivo Bioactivity Assay of rAAV2-hIL15
Nude mice are T-cell defective in which NK cell activity
cannot be determined. Previous research showed that the
increase in the immunoglobulin titer can be an indication
of an increase in the IL15 activity [10]. In addition, it has
been reported that this immunoglobulin is related to anti-
tumor activity on nude mice [27]. Therefore immu-
noglobulin level was determined in this study. Twenty
four (24)-four-week-old female nude mice were pur-
chased from National Laboratory Animal Center (Tai-
wan). All mice were divided into three groups (8 mice/
each group). The first group of mice was injected with 500
μl of rAAV2-hIL15 (1013 viral particles/ml) on one site of
the quadriceps muscles of their hind limbs, the second
group with 500 μl of rAAV2-hrGFP (1013 viral particles/
ml) and the third group with 500 μl of PBS (the steps and
the amount injected were the same as the first group).
After 28 days, the mice sera were collected for immu-
noglobulin measurement. Quantification of immu-
noglobulin levels was performed using immunoglobulin
ELISA kit (Becton, Dickinson and Company) measured at
an optical density 450 nm. The animal studies have been
approved by the animal committee of the Tzu-Chi Gen-
eral Hospital.
Determination of Mice Weight
Twenty four, four-week-old female nude mice were pur-
chased from National Laboratory Animal Center (Tai-
wan). All mice were divided into three groups (8 mice/
group). The first group of mice was injected with 500 μl of
rAAV2-hIL15 (1013 viral particles/ml) on one site of their
quadriceps muscles of the hind limbs, the second group
with 500 μl of rAAV2-hrGFP (1013 viral particles/ml) and
the third group with 500 μl of PBS (the steps and amount
injected were the same as the first group). Every week, the
weight of the treated-mice was determined using elec-
tronic weighing-scale. The animal studies have been
approved by the animal committee of the Tzu-Chi Gen-
eral Hospital.
Animal Study I (Pre-treated with rAAV-IL15)
Twenty four, four-week-old female nude mice were pur-
chased from National Laboratory Animal Center (Tai-
wan). All mice were divided into three groups (8 mice/
group). The first group of mice was injected with 500 μl of
rAAV2-hIL15 (1013 viral particles/ml) on one site of quad-
riceps muscles of their hind limbs, the second group with
500 μl of rAAV2-hrGFP (1013 viral particles/ml) and the
third group with 500 μl of PBS (steps and amount injected
were the same as the first group). After 28 days, 107 HeLa
cells were injected subcutaneously on the lower abdomi-
nal region of all mice. The day when mice began treatment
with HeLa cells corresponded to day zero. After that,
tumor size was measured every week according to the fol-
lowing formula: (A × B2)/2, where A is the greater and B is
the smaller measurement of the two dimensions [28,29].
The animal studies have been approved by the animal
committee of the Tzu-Chi General Hospital.
Animal Study II (Post-treated with rAAV-IL15)
Twenty four, four-week-old female nude mice were pur-
chased from National Laboratory Animal Center (Tai-
wan). All mice were divided into three groups (8 mice/
group) and were injected with 107 HeLa cells on the lower
abdominal region. The next day, the first group of mice
was injected with 500 μl of rAAV2-hIL15 (1013 viral parti-
cles/ml) on one site of quadriceps muscles of the hind
limbs, the second group with 500 μl of rAAV2-hrGFP
(1013 viral particles/ml) and the third group with 500 μl
of PBS (steps and amount injected were the same as the
first group). The day when mice began treatment with
HeLa cells corresponded to day zero. The, tumor size was
then measured according to the following formula: (A ×
B2)/2, where A is the greater and B is the smaller measure-
ment of the two dimensions [28,29]. The animal studies
have been approved by the animal committee of the Tzu-
Chi General Hospital.
Statistical Analysis
The Student t-test was utilized in the analysis of data pre-
sented as the mean ± SE. A value of P < 0.05 was consid-
ered statistically significant.
Results
rAAV2-hIL15 Can Express IL15 Having Bioactivity in vitro
With the use of a helper-free system and SSCP method,
rAAV2-hIL15 and rAAV2-hrGFP were produced and puri-Page 3 of 8
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hIL15 and rAAV2-hrGFP have VP1, VP2 and VP3 of AAV2
capsid proteins. This result is similar to previous study
[26]. HT1080 cells can be infected with AAV2 easily for
production of AAV2 expressing genes. Purified rAAV2-
hIL15, rAAV2-hrGFP and PBS were added to HT1080
cells, respectively. After 2 days, the culture media of
HT1080 cells were collected. For quantification of IL15,
our data showed that the media obtained from rAAV2-
hIL15 treated-HT1080 cells have IL15 of about 500 ng/ml
(Figure 2). However the media obtained from rAAV2-
hrGFP or PBS treated-HT1080 cells have less and less IL15
than rAAV2-hIL15 treated-cells (Figure 2). The data indi-
cated that rAAV2-hIL15 can express IL15. HT2 cells are
IL2/IL15 dependent cells and they cannot survive without
IL15 (or IL2) supply. Therefore the survival rate of HT2
cells can be used as an indicator for IL15 bioactivities. The
media obtained from rAAV2-hIL15, rAAV2-hrGFP-treated
HT1080 cells were collected and added to HT2 cells
respectively. The purified human IL15 added to HT2 cells
was used as a positive control. Observation on HT2 sur-
vival rate, the data showed that HT2 cells can grow with
the media containing purified human IL15 and with the
media obtained from rAAV2-hIL15-treated HT1080 cells
(Figure 3). However, media obtained from rAAV2-hrGFP-
treated HT1080 cells resulted in survival inhibition on
HT2 cells (Figure 3). The morphologies of HT2 cells were
also observed under the microscope (Figure 4). The mor-
phologic data indicated that HT2 cells were able to survive
under the media containing purified human IL15 and the
media obtained from rAAV2-hIL15-treated HT1080 cells.
However, HT2 cells were not able to survive under the
media obtained from rAAV2-hrGFP-treated HT1080 cells
(this result has been demonstrated in figure 3). Taken
together, we successfully produced and purified rAAV2-
hIL15 which has bioactivity in vitro.
rAAV2-hIL15 Induces Immunoglobulin Production in Mice
Sera were collected from mice that were treated by intra-
muscular injection of rAAV2-hIL15, rAAV2-hrGFP and
Purification of hIL15Figure 1
Purification of hIL15. 1010 viral particles were determined 
on 10% SDS page with silver staining. Lane 1 showed rAAV2-
hIL15 and lane 2 showed rAAV2-hrGFP.
Production of hIL15Figure 2
Production of hIL15. H1080 cells were treated with 
rAAV2-hIL15, rAAV2-hrGFP or PBS. After 2 days, media 
were collected and assayed for hIL15 using an ELISA kit. Data 
were obtained from three independent triplicate experi-
ments and were presented as mean ± S.D.
Survival rate of HT2 cellsFigure 3
Survival rate of HT2 cells. Media obtained from rAAV2-
hIL15-infected or rAAV2-hrGFP-infected HT1080 cells were 
added to HT2 cells culture. Media containing 1 μg/ml purified 
hIL15 were added to HT2 cells as a positive control. After 3 
days, survival rate of HT2 cells was determined using MTS 
assay. Data were obtained from three independent triplicate 
experiments and were presented as mean ± S.D.Page 4 of 8
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of immunoglobulins (IgG1, IgG2a, IgG2b, IgA, and IgM).
The data showed that sera obtained from rAAV2-hIL15-
treated mice had higher titers of IgG1 and IgM than sera
obtained from rAAV2-hrGFP-treated and PBS-treated
mice (Figure 5). However, production of IgG2a, IgG2b
and IgA has no significant difference in rAAV2-hIL15-
treated, rAAV2-hrGFP-treated and PBS-treated mice. The
data suggested that rAAV2-hIL15 can induce production
of IgG1 and IgM in nude mice. Furthermore, we examined
whether rAAV2-hIL15 and rAAV2-hrGFP interfered with
mice growth. Our data indicated that during the 18 weeks,
there was no difference in growth rate among mice treated
by rAAV2-hIL15, rAAV2-hrGFP, and PBS (Figure 6).
Pre-treated rAAV2-hIL15 Inhibits Tumor Growth 
Efficiently
Previous study had demonstrated that AAV, a single-
stranded DNA virus, must convert single-stranded DNA
into double stranded templates for transcription [30,31].
This rate-limiting step is achieved in about 3 weeks. There-
fore, we first prescribed rAAV2-hIL15 before tumor
implantation in the mice in this study. After rAAV2-hIL15,
rAAV2-hrGFP and PBS were injected into the muscles of
mice for 28 days, these mice received HeLa tumor cells
implantation by subcutaneous injection. After which,
tumor size was determined every week. Our data showed
that tumor growth rate in rAAV2-hIL15-treated mice was
slower than that in rAAV2-hrGFP- and PBS-treated mice
(Figure 7). Meanwhile, tumor growth rates are similar in
rAAV2-hrGFP-treated and PBS-treated mice. Comparing
the tumor size on rAAV2-hIL15-treated mice with rAAV2-
hrGFP- and PBS-treated mice, the difference in the size of
the tumor becomes greater after the ninth week. These
data indicated that pre-treated rAAV2-hIL15 could sup-
press tumor growth efficiently.
Post-treated rAAV2-hIL15 Delays Tumor Growth
We examined next whether post-treated rAAV2-hIL15 has
an anti-tumor effect. HeLa cells were first injected subcu-
taneously. in the lower abdominal region of the mice. The
next day, these mice were given intramuscular injection of
rAAV2-hIL15, rAAV2-hrGFP and PBS respectively. Before
the 12th week, tumor sizes had no significant differences,
but we found out that the tumor size was smaller in
rAAV2-hIL15 treated-mice than in rAAV2-hrGFP-treated-
mice and PBS-treated mice after 12 weeks (Figure 8). The
Morphology of HT2 cells under a microscopeFigure 4
Morphology of HT2 cells under a microscope. HT2 cells were cultured for 3 days with media obtained from: 1 μg/ml 
purified hIL15 (A), rAAV2-hrGFP infected-HT 1080 cells (B), and rAAV2-hIL15 infected-HT 1080 cells (C).
Immunoglobulin levelsFigure 5
Immunoglobulin levels. Sera obtained from rAAV2-hIL15-
treated, rAAV2-hrGFP-treated and PBS-treated mice for 28 
days were examined, respectively. Quantification of isotype 
levels was performed using the ELISA method. Eight mice 
were determined for each group.Page 5 of 8
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delay tumor growth. Altogether, our studies suggested pre-
treated and post-treated rAAV2-hIL15 are a good
approach for cancer gene therapy, yet pre-treated rAAV2-
hIL15 is more efficient in inhibiting tumor growth.
Discussion
Previous studies have shown that tumors were inhibited
effectively by IL2 or IL15 due to NK cells activation and
immunoglobulins secretion [9,10]. IL15 engineered
tumor cells or daily administration of IL15 can suppress
tumor growth has been demonstrated previously [6,11-
14]. However, daily administration of IL15 is not conven-
ient for cancer treatment because the life span of IL15 is
short, and thus IL15 must be given by i.m. injection for
many days [12,13]. In order to use IL15 for cancer treat-
ment and to avoid treating IL15 many times, gene therapy
is considered. Previous study has used adenoviral vector
expressing IL15 gene for mouse lung cancer treatment
[15]. Although adenovirus vector expressing IL15 gene
can inhibit mouse lung cancer, it is difficult to be applied
on human cancer treatment due to adenovirus vector-
induced cytotoxicity and inflammatory response [16].
Many gene delivery systems have been developed [24,32-
34]. rAAV2 is one of delivery systems for gene therapy and
has many attractive features including long-term trans-
gene expression, low immunogenicity, and lack of appar-
ent pathogenicity [17,18]. Though rAAV2 is a small viral
vector and can only carry about 5000 nucleotides gene
sequence [35], human IL15 gene (about 600 nucleotides)
can be packaged into rAAV2 vector for tumor treatment.
In addition, previous studies showed that muscle can be
used to produce therapeutic proteins encoded by infected
with rAAV2 [36,37]. Northern blot has demonstrated that
expression of IL15 mRNA can be observed in skeletal
muscle [7,38]. Therefore, rAAV2-hIL15 was injected into
the quadriceps muscle of mice in this study.
The study showed that pre-treated rAAV2-hIL15 can
inhibit cervical cancer growth effectively (Figure 7). How-
ever, inhibition of tumor growth was less efficient by post-
treated with rAAV2-hIL15 (Figure 8). Previous reports
indicated that AAV is a single-strand DNA virus and must
convert single-strand DNA into double strand template
for transcription [30,31]. This rate-limiting step takes
about 3 weeks. These previous results indicated that AAV-
Growth rate of animalsFigure 6
Growth rate of animals. All mice were treated with 
rAAV2-hIL15, rAAV2-hrGFP and PBS respectively and the 
mice weight was determined for 18 weeks. Each group used 
eight mice for weight determination.
Tumor volume of HeLa cervical cancers in pre-treated miceFigure 7
Tumor volume of HeLa cervical cancers in pre-
treated mice. Mice were injected I.M. with rAAV2-hIL15, 
rAAV2-hrGFP and PBS respectively. After 28 days, HeLa cells 
were injected S.C. into these mice indicating day zero. Every 
week tumor size of these mice was determined. Eight mice 
were determined for each group.
Tumor volume of HeLa cervical cancers in post-treated miceFigure 8
Tumor volume of HeLa cervical cancers in post-
treated mice. HeLa cells were injected S.C. into the mice 
indicating day zero. Next day, rAAV2-hIL15, rAAV2-hrGFP 
and PBS were injected I.M. to the mice, respectively. Tumor 
size was determined weekly. Eight mice were determined for 
each group.Page 6 of 8
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ment in our study. That is, IL15 has been expressed before
tumor transplantation in our pre-treated rAAV2-hIL15
study, but IL15 was not expressed before 3 weeks with
tumor transplantation in our post-treated rAAV2-hIL15
study. Therefore inhibition of tumor growth was more
efficient when pre-treated with rAAV2-hIL15 for 28 days
while tumor inhibition was less efficient when post-
treated with rAAV2-hIL15. We considered that rAAV2 con-
verted single-strand DNA into double strand template at
the moment. To sum up, conversion of rAAV2 single-
strand DNA into double strand template for gene expres-
sion is very important for gene therapy [31,39]. Based on
this reason, we suggest that using a new rAAV2 vector con-
taining a double-strand DNA genome may overcome this
problem [39]. Additionally, to increase the anti-tumor
effect of rAAV2-hIL15 treatment, combination with other
therapies (such as chemotherapy, radiotherapy, surgical
treatment) will be considered on clinical treatment in the
future.
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